Iterum Therapeutics plc (ITRM) P/E Ratio History
Historical price-to-earnings valuation from 2022 to 2022
Loading P/E history...
ITRM Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Iterum Therapeutics plc (ITRM) trades at a price-to-earnings ratio of -0.0x, with a stock price of $0.03 and trailing twelve-month earnings per share of $-0.59.
The current P/E is 100% below its 5-year average of 26.6x. Over the past five years, ITRM's P/E has ranged from a low of 26.6x to a high of 26.6x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, ITRM trades at a 100% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, ITRM trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ITRM DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ITRM P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $30B | 22.8Lowest | 0.56Best | +5%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
ITRM Historical P/E Data (2022–2022)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2022 Q1 | $5.33 | $0.20 | 26.6x | +0% |
Average P/E for displayed period: 26.6x
See ITRM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ITRM Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ITRM vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonITRM — Frequently Asked Questions
Quick answers to the most common questions about buying ITRM stock.
Is ITRM stock overvalued or undervalued?
ITRM current P/E: -0.0x. 5-year average P/E: 26.6x. Percentile: N/A.
How does ITRM's valuation compare to peers?
Iterum Therapeutics plc P/E of -0.0x compares to sector median of 22.3x. Sector comparison provides relative valuation context.
What is ITRM's PEG ratio?
ITRM PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2022-2022.